July 28, 2016

ProterixBio and the University of Zurich Receive Michael J. Fox Foundation Grant to Develop a Novel Assay for Alpha-synuclein Aggregates

Billerica, MA – ProterixBio, Inc. today announced the receipt of a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant funds a collaboration between ProterixBio and the University of Zurich in Switzerland focused on the development of a novel bioanalytical assay workflow that aims to measure small amounts of aberrant alpha-synuclein… Read more »

July 13, 2016

ProterixBio Announces the Appointment of Dr. Fernando Martinez to its Scientific Advisory Board

Billerica, MA – July 13, 2016 – ProterixBio, Inc. today announced that the company has appointed Fernando Martinez, M.D. to its scientific and medical advisory board. Dr. Martinez is a global clinical expert in pulmonary diseases such as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). This appointment reflects ProterixBio’s strategic focus on developing… Read more »

May 3, 2016

BioScale Announces Company Name Change to ProterixBio and New Focus on Pulmonary Diagnostics and Disease Management

Billerica, MA, May 3, 2016 – BioScale, Inc. today announced that the company is changing its name to ProterixBio, Inc. The name change reflects a new strategic direction centered on high value clinical applications including diagnostics products and disease management services. ProterixBio is developing innovative products to transform the management of chronic diseases, with the… Read more »